Answers are grounded in this paper and cite their sources.
A hybrid ‘clusterbomb’ nanovaccine is exploited to overcome the antigen delivery challenge by a one trigger-multiple response strategy for brain tumor immunotherapy.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: